The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Selecting a therapy for patients with ITP and additional comorbidities
In this video, Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, briefly discusses treatment selection in patients with immune thrombocytopenia (ITP) and additional comorbidities, highlighting the importance of shared decision-making and considering how a therapy’s side-effect profile may overlap with underlying comorbidities. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
